1. Home
  2. SEMR vs ZYME Comparison

SEMR vs ZYME Comparison

Compare SEMR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEMrush Holdings Inc.

SEMR

SEMrush Holdings Inc.

HOLD

Current Price

$11.81

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$23.07

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEMR
ZYME
Founded
2008
2003
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
SEMR
ZYME
Price
$11.81
$23.07
Analyst Decision
Hold
Strong Buy
Analyst Count
5
9
Target Price
$10.00
$32.75
AVG Volume (30 Days)
1.8M
594.4K
Earning Date
03-04-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$428,627,000.00
$134,481,000.00
Revenue This Year
$20.35
$63.10
Revenue Next Year
$14.87
$93.26
P/E Ratio
N/A
N/A
Revenue Growth
19.87
116.21
52 Week Low
$6.56
$9.03
52 Week High
$18.01
$28.49

Technical Indicators

Market Signals
Indicator
SEMR
ZYME
Relative Strength Index (RSI) 51.11 48.12
Support Level $11.81 $22.07
Resistance Level $11.88 $23.52
Average True Range (ATR) 0.03 0.88
MACD -0.03 0.09
Stochastic Oscillator 4.17 60.44

Price Performance

Historical Comparison
SEMR
ZYME

About SEMR SEMrush Holdings Inc.

SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: